Aimovig Archives -

Market Access/ News/ News/ Top stories

NICE backs Lilly’s Emgality for migraine, adding pressure on Novartis

Phil Taylor Aimovig, Ajovy, chronic migraine, Eli Lilly, Emgality, episodic migraine, NICE, Novartis, Teva 0 Comment

UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for

NICE backs Lilly’s Emgality for migraine, adding pressure on Novartis

https://pharmaphorum.com/news/nice-backs-lillys-emgality-for-migraine-adding-pressure-on-novartis-rival/

News/ News/ R&D/ Top stories

Novartis’ Aimovig tops topiramate in migraine face-off

Phil Taylor Aimovig, Amgen, CGRP, migraine, neurology, Novartis, prevention 0 Comment

Novartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to

Novartis’ Aimovig tops topiramate in migraine face-off

https://pharmaphorum.com/news/novartis-aimovig-tops-topiramate-in-migraine-face-off/

Market Access/ News/ News/ Top stories

After rejection, NICE agrees to look again at migraine drug Aimovig

Phil Taylor Aimovig, CGRP, migraine, neurology, NHS, NICE, Novartis 0 Comment

The UK’s medicines cost-effectiveness agency NICE has agreed to look again at its decision to turn down NHS

After rejection, NICE agrees to look again at migraine drug Aimovig

https://pharmaphorum.com/news/nice-migraine-aimovig/

Market Access/ News/ News/ News/ Patients

Blow to Novartis as NICE rejects migraine drug Aimovig again

Phil Taylor Aimovig, chronic migraine, migraine, NICE, Novartis, UK 0 Comment

After NICE rejected Novartis’ migraine prevention drug Aimovig in draft guidance issued in January, it was inundated with

Blow to Novartis as NICE rejects migraine drug Aimovig again

https://pharmaphorum.com/news/blow-to-novartis-as-nice-rejects-migraine-drug-aimovig-again/

News/ News/ Sales and Marketing

Cancer update buoys Amgen despite Q2 sales fall

Phil Taylor Aimovig, Amgen, Evenity, financial results, Neulasta, Oncology, Repatha 0 Comment

Amgen’s second quarter revenues were down 3% as competition pegged back its off-patent drugs Sensipar and Neulasta, but

Cancer update buoys Amgen despite Q2 sales fall

https://pharmaphorum.com/news/cancer-update-buoys-amgen-despite-q2-sales-fall/

Market Access/ News/ News

Scotland backs Aimovig for migraine after NICE says no

Phil Taylor Aimovig, migraine, NICE 0 Comment

People suffering from severe migraines in Scotland will be able to get treatment with Amgen and Novartis’ Aimovig

Scotland backs Aimovig for migraine after NICE says no

https://pharmaphorum.com/news/scotland-backs-aimovig-for-migraine-after-nice-says-no/

Market Access/ News/ News/ Top stories

NICE rejects Novartis’ migraine prevention drug Aimovig

Phil Taylor Aimovig, migraine, Novartis 0 Comment

Some migraine sufferers in the UK hoping to get access to Novartis’ new migraine prevention drug Aimovig are

NICE rejects Novartis’ migraine prevention drug Aimovig

https://pharmaphorum.com/news/nice-rejects-novartis-migraine-prevention-drug-aimovig/

News/ Patients/ R&D/ Top stories/ UK & Europe

Breakthrough migraine prevention treatment approved in Europe

Piotr Wnuk Aimovig, chronic migraine, episodic migraine, migraine, neurology, Novartis 0 Comment

Novartis’ Aimovig (erenumab) has been approved by the European Medicines Agency (EMA) making it first self-administered, monthly migraine

Breakthrough migraine prevention treatment approved in Europe

https://pharmaphorum.com/news/breakthrough-migraine-prevention-treatment-approved-in-europe/

Market Access/ News/ News

Migraine prevention drug Aimovig poised for EU approval

Joy Persaud Aimovig, chronic migraine, episodic migraine, Novartis 0 Comment

The first antibody treatment to prevent migraine (Aimovig), produced by Novartis, is on the cusp of approval. The

Migraine prevention drug Aimovig poised for EU approval

https://pharmaphorum.com/news/migraine-prevention-aimovig-eu-approval/

Trending

Aimovig

Login